Forest To Test Alzheimer’s Drug Neramexane As Monotherapy in Phase II/III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The NMDA receptor agonist failed to show efficacy as a combination therapy with acetylcholinesterase inhibitors in pivotal trial for moderate-to-severe disease, Forest says.
You may also be interested in...
Desmoteplase Approval For Stroke Expected In 2009, Forest Says
Nine-hour treatment window could expand market. A Phase IIb/III dose-ranging study is underway. Desmoteplase is one of a handful of late-stage opportunities for Forest; the company will be in a quiet period in terms of product approvals until late in the decade.
Desmoteplase Approval For Stroke Expected In 2009, Forest Says
Nine-hour treatment window could expand market. A Phase IIb/III dose-ranging study is underway. Desmoteplase is one of a handful of late-stage opportunities for Forest; the company will be in a quiet period in terms of product approvals until late in the decade.
Forest Namenda Has 10% Off-Label Use Based On Initial Launch Data
The company said 70% of use was in moderate Alzehimer's cases and 20% was in severe cases. The company expects to file an sNDA for a mild-to-moderate indication by "late this summer."